Observations placeholder
Oncovin
Identifier
019806
Type of Spiritual Experience
Number of hallucinations: 8
Background
A description of the experience
Vincristine, also known as leurocristine and marketed under the brandname Oncovin among others, is a chemotherapy medication used to treat a number of types of cancer. This includes acute lymphocytic leukemia, acute myeloid leukemia, Hodgkin's disease, neuroblastoma, and small cell lung cancer among others. It is given intravenously.
Most people experience some side effects from vincristine treatment. Commonly it causes a change in sensation, hair loss, constipation, difficulty walking, and headaches. Serious side effects may include neuropathic pain, lung damage, or low blood white cells. It will likely cause harm to an infant if given during pregnancy. It works by stopping cells from dividing properly.
On Jan, 28, 2016: 3,187 people reported to have side effects when taking Oncovin. Among them, 8 people (0.25%) have Hallucination.
Time on Oncovin when people have Hallucination :
| n/a |
Gender of people who have Hallucination when taking Oncovin :
| Female | Male | |
| Hallucination | 50.00% | 50.00% |
Age of people who have Hallucination when taking Oncovin :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Hallucination | 0.00% | 20.00% | 20.00% | 0.00% | 0.00% | 0.00% | 0.00% | 60.00% |
On Jan, 28, 2016: 3,187 people reported to have side effects when taking Oncovin. Among them, 50 people (1.57%) have Death.
Time on Oncovin when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 30.00% | 60.00% | 10.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Oncovin :
| Female | Male | |
| Death | 23.08% | 76.92% |
Age of people who have Death when taking Oncovin :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 2.13% | 0.00% | 4.26% | 8.51% | 4.26% | 21.28% | 59.57% |
Top conditions involved for these people :
- Lymphoma (9 people, 18.00%)
- Chronic myeloid leukaemia (7 people, 14.00%)
- Non-hodgkin's lymphoma (3 people, 6.00%)
- Follicle centre lymphoma, follicular grade i, ii, iii stage iv (3 people, 6.00%)
- Burkitt's lymphoma (2 people, 4.00%)